

**In the claims:**

This listing of the claims will replace all prior versions and listings of the claims in the application:

We claim:

1. **(Currently Amended)** A method of inducing proliferation, growth, or survival of a hypoproliferative cell ~~treating a hypoproliferative cell disorder or disorder involving increased cell death in a patient in need thereof~~, said method comprising administering to said patient a therapeutically contacting said cell with an effective amount of an EphA2 antagonistic agent, wherein said agent is an antibody or an antigen binding fragment thereof.

2. - 4. **(Canceled)**

5. **(Currently Amended)** The method of claim 1 wherein said ~~administration~~ method increases the proliferation or survival of an epithelial cell relative to the level of proliferation or survival in an untreated epithelial ~~and/or endothelial~~ cell.

6. **(Currently Amended)** The method of claim 1 wherein said ~~administration~~ method increases the proliferation or survival of an endothelial cell relative to the level of proliferation or survival in an untreated ~~epithelial and/or~~ endothelial cell.

7. **(Currently Amended)** The method of claim 1 wherein said ~~administration~~ method decreases EphA2 cytoplasmic tail phosphorylation relative to the untreated level of EphA2 cytoplasmic tail phosphorylation.

8. - 9. **(Canceled)**

10. **(Currently Amended)** The method of claim 1 wherein said ~~administration~~ method increases EphA2 gene expression or translation.

11. **(Canceled)**

12. **(Currently Amended)** The method of claim 1 wherein said EphA2 antagonistic agent is an anti-EphA2 antibody or antigen binding fragment thereof.

13. **(Currently Amended)** The method of claim [[12]]1 wherein said EphA2 antagonistic agent is an anti-EphrinA1 antibody or antigen binding fragment thereof.

14. **(Currently Amended)** The method of claim [[12]]1 wherein the said antibody is a monoclonal antibody.

15. **(Currently Amended)** The method of claim [[14]]1 wherein said monoclonal antibody is a human antibody.

16. **(Currently Amended)** The method of claim [[14]]1 wherein said monoclonal antibody is humanized.

17. **(Canceled)**

18. **(Original)** The method of claim 1 wherein said antagonistic agent increases EphA2 protein stability or protein accumulation.

19. **(Currently Amended)** The method of claim 1 wherein said ~~administration~~ method decreases EphA2-endogenous ligand binding relative to the amount of untreated EphA2-endogenous ligand binding.

20. **(Original)** The method of claim 19 wherein said endogenous ligand is Ephrin-A1.

21. - 23. **(Canceled)**